Cardioprotective properties of glucagon-like peptide-1 receptor agonists in type 2 diabetes mellitus patients: A systematic review.

Widiarti W, Sukmajaya AC, Nugraha D, Alkaff FF

Diabetes & metabolic syndrome15 Apr 2021Cited by 8 (Europe PMC)

PMID33866119DOI10.1016/j.dsx.2021.04.005PepBankPUB-33866119

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone7

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

01HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In adults with type 2 diabetes, pooled GLP-1 receptor agonists (liraglutide or exenatide) caused weight loss in all included studies.
In plain wordsIn adults with type 2 diabetes, the GLP-1 drug class (liraglutide or exenatide) was linked to weight loss in all included studies.
Peptide
Liraglutide
Outcome
DecreaseWeight loss
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Source sentences
Summary
All studies showed that GLP-1 RA significantly caused weight loss and improved cardiac functional capacity by increasing left ventricular ejection fraction and reducing end-systolic and end-diastolic left ventricle volume.
1 context sentence(design, population, supporting numbers)
Summary · context
A total of six studies (4 randomized, 2 observational) with a total of 182.205 patients were included in this review.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3386611901
02HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In adults with type 2 diabetes, pooled GLP-1 receptor agonists (liraglutide or exenatide) increased left ventricular ejection fraction.
In plain wordsIn adults with type 2 diabetes, the GLP-1 drug class (liraglutide or exenatide) was linked to better heart pumping function.
Peptide
Liraglutide
Outcome
IncreaseLeft ventricular ejection fraction
Study
n: not reported in source
Outcome group
Heart function · Cardiovascular
Source sentences
Summary
All studies showed that GLP-1 RA significantly caused weight loss and improved cardiac functional capacity by increasing left ventricular ejection fraction and reducing end-systolic and end-diastolic left ventricle volume.
1 context sentence(design, population, supporting numbers)
Summary · context
A total of six studies (4 randomized, 2 observational) with a total of 182.205 patients were included in this review.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3386611902
03HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In adults with type 2 diabetes, pooled GLP-1 receptor agonists (liraglutide or exenatide) reduced end-systolic and end-diastolic left ventricle volume.
In plain wordsIn adults with type 2 diabetes, the GLP-1 drug class (liraglutide or exenatide) was linked to smaller heart chamber volumes.
Peptide
Liraglutide
Outcome
DecreaseEnd-systolic and end-diastolic left ventricle volume
Study
n: not reported in source
Outcome group
Heart function · Cardiovascular
Source sentences
Summary
All studies showed that GLP-1 RA significantly caused weight loss and improved cardiac functional capacity by increasing left ventricular ejection fraction and reducing end-systolic and end-diastolic left ventricle volume.
1 context sentence(design, population, supporting numbers)
Summary · context
A total of six studies (4 randomized, 2 observational) with a total of 182.205 patients were included in this review.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3386611903
04HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In adults with type 2 diabetes, pooled GLP-1 receptor agonists (liraglutide or exenatide) improved myocardial blood flow.
In plain wordsIn adults with type 2 diabetes, the GLP-1 drug class (liraglutide or exenatide) was linked to better blood flow in the heart muscle.
Peptide
Liraglutide
Outcome
IncreaseMyocardial blood flow
Study
n: not reported in source
Outcome group
Heart function · Cardiovascular
Source sentences
Summary
GLP-1 RA also improved myocardial blood flow without affecting myocardial glucose uptake.
1 context sentence(design, population, supporting numbers)
Summary · context
A total of six studies (4 randomized, 2 observational) with a total of 182.205 patients were included in this review.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3386611904
05HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In adults with type 2 diabetes, pooled GLP-1 receptor agonists (liraglutide or exenatide) did not affect myocardial glucose uptake.
In plain wordsIn adults with type 2 diabetes, the GLP-1 drug class (liraglutide or exenatide) did not change glucose uptake in the heart muscle.
Peptide
Liraglutide
Outcome
No significant changeMyocardial glucose uptake
Study
n: not reported in source
Outcome group
Heart function · Cardiovascular
Source sentences
Summary
GLP-1 RA also improved myocardial blood flow without affecting myocardial glucose uptake.
1 context sentence(design, population, supporting numbers)
Summary · context
A total of six studies (4 randomized, 2 observational) with a total of 182.205 patients were included in this review.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3386611905
06HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In adults with type 2 diabetes, pooled GLP-1 receptor agonists (liraglutide or exenatide) failed to reduce blood pressure.
In plain wordsIn adults with type 2 diabetes, the GLP-1 drug class (liraglutide or exenatide) did not lower blood pressure in these studies.
Peptide
Liraglutide
Outcome
No significant changeBlood pressure
Study
n: not reported in source
Outcome group
Blood pressure · Cardiovascular
Source sentences
Summary
GLP-1 RA failed to show its effect in reducing blood pressure and improving lipid profiles.
1 context sentence(design, population, supporting numbers)
Summary · context
A total of six studies (4 randomized, 2 observational) with a total of 182.205 patients were included in this review.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3386611906
07HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In adults with type 2 diabetes, pooled GLP-1 receptor agonists (liraglutide or exenatide) failed to improve lipid profiles.
In plain wordsIn adults with type 2 diabetes, the GLP-1 drug class (liraglutide or exenatide) did not improve blood fats in these studies.
Peptide
Liraglutide
Outcome
No significant changeLipid profile
Study
n: not reported in source
Outcome group
Lipids · Cardiovascular
Source sentences
Summary
GLP-1 RA failed to show its effect in reducing blood pressure and improving lipid profiles
1 context sentence(design, population, supporting numbers)
Summary · context
A total of six studies (4 randomized, 2 observational) with a total of 182.205 patients were included in this review.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3386611907

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 11:11 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.